Medicus Pharma Ltd.
corporate_fare Company Profile
Medicus Pharma Ltd. (NASDAQ:MDCX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 31 items for MDCX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-03, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 18 rated 8 or above. Recent SEC coverage for MDCX spans 8-K, 10-Q, 424B3, DEF 14A.
Recent high-impact activity:
- Medicus Pharma Secures $1B+ Global License from Pfizer for CD228V ADC
- Medicus Pharma Inks Pfizer Co-Development Deal for CD228V ADC — $27M Upfront, $1B+ Milestones
- Medicus Pharma Q2 Loss Widens to $11.7M as R&D Spend Triples
- Medicus Pharma Q2 Loss Widens to $11.7M; Going Concern Doubt Persists
- UAE Regulator Greenlights Phase 2a Trial for Teverelix
Financial Snapshot
Dilution Risk
High riskFiling-implied dilution signals for MDCX, detected from its recent SEC filings · based on capital-structure filings through 2026-09-11.
Highly Dilutive ATM Sales · Going Concern Warning
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →